ICU Medical (NASDAQ:ICUI) Downgraded to Hold Rating by Zacks Research

ICU Medical (NASDAQ:ICUI) was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report issued on Tuesday,Zacks.com reports.

Other analysts have also issued reports about the stock. Sanford C. Bernstein lowered shares of ICU Medical to a “market perform” rating in a research note on Monday, June 15th. BTIG Research began coverage on shares of ICU Medical in a research note on Monday, June 15th. They issued a “buy” rating and a $170.00 price objective for the company. Weiss Ratings upgraded ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 23rd. Piper Sandler reduced their price target on ICU Medical from $178.00 to $163.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Finally, Needham & Company LLC upgraded ICU Medical from a “hold” rating to a “buy” rating and set a $165.00 price objective for the company in a research note on Wednesday, May 27th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, ICU Medical presently has a consensus rating of “Moderate Buy” and a consensus price target of $172.00.

ICU Medical Stock Up 0.5%

Shares of NASDAQ ICUI opened at $166.53 on Tuesday. ICU Medical has a 52-week low of $107.00 and a 52-week high of $170.48. The firm has a market capitalization of $4.16 billion, a price-to-earnings ratio of 90.02, a PEG ratio of 2.32 and a beta of 0.76. The stock has a 50 day moving average price of $146.57 and a 200 day moving average price of $140.00. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.17 and a current ratio of 2.34.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.97 EPS for the quarter, topping the consensus estimate of $1.78 by $0.19. The company had revenue of $525.77 million for the quarter, compared to the consensus estimate of $520.65 million. ICU Medical had a return on equity of 7.50% and a net margin of 2.15%.ICU Medical’s quarterly revenue was down 12.3% on a year-over-year basis. During the same period last year, the business posted $1.72 EPS. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. Sell-side analysts expect that ICU Medical will post 6.51 earnings per share for the current year.

Insider Activity at ICU Medical

In related news, Director David C. Greenberg sold 2,424 shares of the stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total transaction of $297,933.84. Following the completion of the sale, the director owned 7,960 shares of the company’s stock, valued at $978,363.60. This represents a 23.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Virginia Ruth Sanzone sold 2,447 shares of the stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $124.08, for a total transaction of $303,623.76. Following the sale, the vice president directly owned 19,460 shares of the company’s stock, valued at $2,414,596.80. The trade was a 11.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 2.10% of the company’s stock.

Institutional Trading of ICU Medical

Hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its stake in ICU Medical by 3.4% during the 4th quarter. Vanguard Group Inc. now owns 2,714,746 shares of the medical instruments supplier’s stock worth $387,313,000 after buying an additional 89,755 shares during the last quarter. Janus Henderson Group PLC raised its stake in ICU Medical by 3.9% in the first quarter. Janus Henderson Group PLC now owns 2,676,012 shares of the medical instruments supplier’s stock valued at $345,607,000 after buying an additional 99,256 shares during the last quarter. Millennium Management LLC boosted its holdings in ICU Medical by 173.4% in the third quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier’s stock worth $130,638,000 after acquiring an additional 690,694 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in ICU Medical by 6.8% in the first quarter. Dimensional Fund Advisors LP now owns 983,802 shares of the medical instruments supplier’s stock worth $127,053,000 after acquiring an additional 63,026 shares in the last quarter. Finally, State Street Corp grew its stake in shares of ICU Medical by 2.8% during the fourth quarter. State Street Corp now owns 942,670 shares of the medical instruments supplier’s stock worth $134,491,000 after acquiring an additional 25,545 shares during the last quarter. Hedge funds and other institutional investors own 96.10% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.